San Diego, California–(Newsfile Corp. – December 16, 2022) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
San Diego, California–(Newsfile Corp. – December 13, 2022) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives,...
San Diego, California–(Newsfile Corp. – November 22, 2022) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
San Diego, California–(Newsfile Corp. – November 17, 2022) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives,...
– Recruitment for cohort 1 has begun – Clinical trial material manufactured and shipped to Australia San Diego, California–(Newsfile Corp. – November 16, 2022) – Skye...
San Diego, California–(Newsfile Corp. – November 10, 2022) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
Skye will continue to pursue Canadian Securities Exchange listing following closing of transaction Vancouver, British Columbia–(Newsfile Corp. – November 7, 2022) – Emerald Health Therapeutics, Inc....
Additional capital from Arrangement Agreement expected to fund Skye’s Phase 1 and 2 clinical studies of proprietary synthetic cannabinoid-derivative therapeutic targeting glaucoma San Diego, California–(Newsfile Corp....
Vancouver, British Columbia–(Newsfile Corp. – August 26, 2022) – Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) (“Emerald” or the “Company”) reports that on August 25, 2022,...
Vancouver, British Columbia–(Newsfile Corp. – August 12, 2022) – Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) (“Emerald” or the “Company”) is providing an update and additional...